MX380677B - Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. - Google Patents

Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.

Info

Publication number
MX380677B
MX380677B MX2018013164A MX2018013164A MX380677B MX 380677 B MX380677 B MX 380677B MX 2018013164 A MX2018013164 A MX 2018013164A MX 2018013164 A MX2018013164 A MX 2018013164A MX 380677 B MX380677 B MX 380677B
Authority
MX
Mexico
Prior art keywords
dioxygenase
tryptophan
indolamine
inhibitors
substituted imidazopyridine
Prior art date
Application number
MX2018013164A
Other languages
English (en)
Other versions
MX2018013164A (es
Inventor
Alan Wise
Hongjun Zhang
Hua Zhou
Kun Liu
Meredeth Ann Mcgowan
Phillip M Cowley
Qinglin Pu
Thomas J Brown
Yongxin Han
Original Assignee
Merck Sharp & Dohme Llc
Iomet Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Iomet Pharma Ltd filed Critical Merck Sharp & Dohme Llc
Publication of MX2018013164A publication Critical patent/MX2018013164A/es
Publication of MX380677B publication Critical patent/MX380677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan aquí compuestos de imidazopiridina sustituida de fórmula (I) que son inhibidores de las enzimas indolamina-2,3-dioxigenasa (IDO) y/o triptófano-2,3-dioxigenasa (TDO): (ver Fórmula) También se divulgan aquí los usos de los compuestos en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO y/o TDO. También se divulgan aquí composiciones que comprenden estos compuestos. Además, se divulgan aquí los usos de las composiciones en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO y/o TDO.
MX2018013164A 2016-04-29 2017-04-24 Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. MX380677B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662329579P 2016-04-29 2016-04-29
PCT/US2017/029042 WO2017189386A1 (en) 2016-04-29 2017-04-24 Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase

Publications (2)

Publication Number Publication Date
MX2018013164A MX2018013164A (es) 2019-06-24
MX380677B true MX380677B (es) 2025-03-12

Family

ID=60161057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013164A MX380677B (es) 2016-04-29 2017-04-24 Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.

Country Status (11)

Country Link
US (1) US11096930B2 (es)
EP (1) EP3448522B1 (es)
JP (1) JP6948345B2 (es)
KR (1) KR102456521B1 (es)
CN (1) CN109069873B (es)
AU (1) AU2017257377B2 (es)
BR (1) BR112018071602B1 (es)
CA (1) CA3021589A1 (es)
MX (1) MX380677B (es)
RU (1) RU2741911C2 (es)
WO (1) WO2017189386A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997682A (zh) 2017-08-17 2020-04-10 爱杜西亚药品有限公司 吲哚胺2,3-二氧酶及/或色氨酸2,3-二氧酶的抑制剂
US20200405696A1 (en) 2018-01-15 2020-12-31 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
CN112312904B (zh) 2018-04-16 2025-01-07 C4医药公司 螺环化合物
WO2019206800A1 (en) * 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021005222A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
KR102642194B1 (ko) 2019-10-11 2024-03-05 삼성전자주식회사 전압 컨트롤러 및 이를 포함하는 메모리 장치

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
PL2315756T3 (pl) * 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
ES2674451T3 (es) * 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
RU2667509C2 (ru) * 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
MA38483A1 (fr) * 2013-03-15 2018-02-28 Bristol Myers Squibb Co Inhibiteurs de l'ido
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
CN106661033B (zh) * 2014-05-28 2018-11-06 阿斯利康(瑞典)有限公司 用于制备azd5363的方法和在其中使用的新颖中间体
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
AU2015341913B2 (en) 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound

Also Published As

Publication number Publication date
RU2018140732A3 (es) 2020-06-02
JP6948345B2 (ja) 2021-10-13
BR112018071602B1 (pt) 2024-02-27
RU2018140732A (ru) 2020-05-29
KR102456521B1 (ko) 2022-10-20
RU2741911C2 (ru) 2021-01-29
EP3448522A4 (en) 2019-11-27
MX2018013164A (es) 2019-06-24
CA3021589A1 (en) 2017-11-02
AU2017257377A1 (en) 2018-10-11
KR20190003619A (ko) 2019-01-09
US20200230117A1 (en) 2020-07-23
EP3448522A1 (en) 2019-03-06
AU2017257377B2 (en) 2022-06-23
EP3448522B1 (en) 2021-01-20
CN109069873B (zh) 2021-07-20
BR112018071602A2 (pt) 2019-02-12
US11096930B2 (en) 2021-08-24
CN109069873A (zh) 2018-12-21
JP2019515923A (ja) 2019-06-13
WO2017189386A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
MX380677B (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
PH12015502028A1 (en) Ido inhibitors
EA201790806A1 (ru) Иммунорегулирующие средства
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
ECSP18083519A (es) Inhibidores de bromodominios
EA201892147A1 (ru) Бициклические соединения
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790992A1 (ru) Иммунорегуляторные агенты
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).